(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.14%) $0.800
(-0.07%) $92.11
Quarter results today
(bmo 2024-04-28)
Expected move: +/- 0.00%
0.00% € 0.290
Live Chart Being Loaded With Signals
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology...
Stats | |
---|---|
Volumen de hoy | 112 228 |
Volumen promedio | 0.00 |
Capitalización de mercado | 27.24M |
EPS | €0 ( 2024-04-17 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.320 |
ATR14 | €0.00700 (2.41%) |
Volumen Correlación
Biocartis Group NV Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Biocartis Group NV Correlación - Moneda/Commodity
Biocartis Group NV Finanzas
Annual | 2022 |
Ingresos: | €57.48M |
Beneficio Bruto: | €27.68M (48.16 %) |
EPS: | €-1.080 |
FY | 2022 |
Ingresos: | €57.48M |
Beneficio Bruto: | €27.68M (48.16 %) |
EPS: | €-1.080 |
FY | 2021 |
Ingresos: | €48.27M |
Beneficio Bruto: | €14.35M (29.72 %) |
EPS: | €-0.895 |
FY | 2020 |
Ingresos: | €43.13M |
Beneficio Bruto: | €16.84M (39.06 %) |
EPS: | €-1.110 |
Financial Reports:
No articles found.
Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico